Compare Baxter International Inc (BAX) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Vistra Corp — how do they compare? Baxter International Inc trades at $21.78 (market cap $11.26B), while Vistra Corp trades at $159.7 (market cap $53.42B). The key difference: Vistra Corp is far larger — about 4.7× Baxter International Inc's market cap, and Baxter International Inc pays the higher dividend (0.92%). Which is the better fit depends on your goals.
| BAX | VST | |
|---|---|---|
Market Cap | $11.26B | $53.42B |
Sector | Health | Technology |
52-Week High | $29.22 | $217.92 |
52-Week Low | $15.80 | $134.71 |
Enterprise Value | $18.93B | $75.17B |
Dividend Yield | 0.92% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
Vistra Corp. (VST) trades at $158.12, down 0.47% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2026 earnings beating estimates, with revenue growth from $17.74B in 2025 to $19.4B projected for 2026. Net income margin improved to 11.52%, supported by robust cash flow from operations of $4.07B. Recent news highlights Vistra's positioning in the AI power demand surge and long-term power purchase agreements with major tech firms.
Outlook remains positive with a consensus price target of $230.50, implying significant upside. Key opportunities include exposure to growing electricity demand and strategic renewables focus. Risks involve power-price volatility, high debt levels, and execution of growth projects. Analyst sentiment is strongly bullish with 91% buy ratings, though investors should monitor Q2 2026 earnings due August 7 for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
